Items where authors include "Gregory, W."

Article

Petruk, N., Wood, S.L., Gregory, W. et al. (7 more authors) (2025) Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use. Scientific Reports, 15 (1). 9449. ISSN 2045-2322

Sitch, A.J., Dinnes, J., Hewison, J. et al. (3 more authors) (2024) Optimising research investment by simulating and evaluating monitoring strategies to inform a trial: a simulation of liver fibrosis monitoring. BMC Medical Research Methodology, 24 (1). 315. ISSN 1471-2288

Collinson, F. orcid.org/0000-0001-6964-6406, Royle, K.-L. orcid.org/0000-0003-0225-1199, Swain, J. orcid.org/0000-0003-2729-3029 et al. (28 more authors) (2024) Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. Health Technology Assessment, 28 (45). ISSN 1366-5278

Jenner, M.W., Pawlyn, C., Davies, F.E. et al. (15 more authors) (2023) The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology, 201 (2). pp. 267-279. ISSN 0007-1048

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Chan, V.W.-S. orcid.org/0000-0002-6108-9315, Osman, F.H., Cartledge, J. et al. (9 more authors) (2022) Long-term outcomes of image-guided ablation and laparoscopic partial nephrectomy for T1 renal cell carcinoma. European Radiology, 32 (9). pp. 5811-5820. ISSN 0938-7994

D'Oronzo, S., Gregory, W., Nicholson, S. et al. (3 more authors) (2021) Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences. Journal of Bone Oncology, 28. 100367. ISSN 2212-1374

Coleman, R.E., Collinson, M., Gregory, W. et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). JOURNAL OF BONE ONCOLOGY, 13. pp. 123-135. ISSN 2212-1374

Brown, J., Rathbone, E., Hinsley, S. et al. (13 more authors) (2018) Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. JNCI: Journal of the National Cancer Institute, 110 (8). pp. 871-879. ISSN 0027-8874